Wuhan Dazhong Dental Med Co (2651) Fair Value & Analysis
Healthcare · HK · Market cap HK$953M
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$13.26 to HK$14.60 (+10.1%) since Aug 5, 2026. Share price +2.8% over the past month.
A solid business, but screening 25% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$18.25). The favourable scenario is already priced in.
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (13 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
13‑month range HK$7.23 – HK$19.70 · fair‑value band HK$10.95 – HK$18.25 · the HK$19.40 price screens above the HK$14.60 fair value. As of Aug 13, 2026.
Analysis
Wuhan Dazhong Dental Med Co (2651) currently trades at HK$19.40, while our model-based Fair Value estimate is HK$14.60, implying the stock looks roughly 24.7% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Wuhan Dazhong Dental Med Co generated revenue of HK$372M at a net margin of 7.6%. Revenue declined 8.3% year over year. It earns a return on equity of 19.0%. The stock trades on a trailing P/E of 26.1 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$10.95 (bear case) to HK$18.25 (bull case); at HK$19.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 172% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -25%, 2651 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (HK$37.34) versus Asset-Based (HK$4.34). Highest evidence: Growth DCF (80).
Notify me when 2651 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Wuhan Dazhong Dental Medical Co., Ltd., together with its subsidiaries, operates as a private dental services provider in China.
Full company description
Wuhan Dazhong Dental Medical Co., Ltd., together with its subsidiaries, operates as a private dental services provider in China. The company offers oral preventive care, treatment of regular oral diseases, and restorative services; implanting artificial teeth root services; and prevention and treatment of dental and jawbone developmental abnormalities, including misaligned teeth, abnormal occlusion, and irregularities in the size, shape, and position of the jawbone. It also provides beauty repair, pediatric dentistry, periodontal treatment, and comprehensive oral treatment services. Wuhan Dazhong Dental Medical Co., Ltd. was formerly known as Wuhan Dazhong Dental Clinic Co., Ltd. and changed its name to Wuhan Dazhong Dental Medical Co., Ltd. in May 2017. The company was incorporated in 2007 and is headquartered in Wuhan, China. Wuhan Dazhong Dental Medical Co., Ltd. operates as a subsidiary of Hubei Zhongshan Medical Investment Management Co.,Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2013 – FY2025 · reported fiscal years
Wuhan Dazhong Dental Med Co reported revenue of HK$372M in FY2025 versus HK$22.2M in FY2013, a compound +26.5%/yr. Reported net income was HK$28.2M in FY2025, compounding +31.6%/yr from FY2013.
2651 screens 25% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 266 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare Wuhan Dazhong Dental Med Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wuhan Dazhong Dental Med Co (2651) overvalued or undervalued?
What is the fair value of 2651?
What is the quality score of 2651?
What is the revenue of Wuhan Dazhong Dental Med Co (2651)?
What is the net profit margin of 2651?
Does Wuhan Dazhong Dental Med Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Wuhan Dazhong Dental Med Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.